BPC-157 is the strength community's favorite peptide — and the one with the most pre-clinical research behind it. If you've heard of "the recovery peptide," "BPC," or some variation of "the gastric juice peptide," you've heard of BPC-157.
This guide is the orientation we wish we'd had: what BPC-157 actually is, what the research does and doesn't show, how people dose it, what side effects to watch, and where to be skeptical of the marketing. Each section links to a deeper cluster page if you want to keep going.
What BPC-157 actually is
BPC-157 stands for Body Protective Compound 157. It's a 15-amino-acid synthetic peptide derived from a larger protective protein, BPC, originally isolated from human gastric juice. Unlike most peptides, it's stable in stomach acid — which is part of why oral dosing is even on the table.
The mechanism isn't fully nailed down, but the leading hypotheses involve:
- Angiogenesis — promoting new blood vessel formation at injury sites, which speeds healing
- Growth factor upregulation — particularly VEGF, FGF, and TGF-beta, which orchestrate tissue repair
- Nitric oxide modulation — affecting circulation and the inflammatory response
- Gut barrier protection — restoring mucosal integrity in the digestive tract
It does not bind to a single receptor like GH or GLP-1. Its effects are pleiotropic, which is part of why it's hard to study cleanly.
What the research says
Almost all BPC-157 research is pre-clinical — rats, mice, and isolated tissue. There are no large randomized controlled trials in humans. The animal data is consistently positive on:
- Achilles tendon transection healing
- Medial collateral ligament injury
- Muscle laceration recovery
- Gastric ulcer protection
- Inflammatory bowel disease models
- Brain injury and stroke models
What we don't have is human Phase 2 or Phase 3 data. The strength community's adoption is driven by pre-clinical promise plus a large body of N-of-1 self-experimentation — not by a regulatory pathway.
For a deeper look at where the science actually is, see BPC-157 research summary.
How BPC-157 is typically dosed
This is education, not a prescription. Reported protocols in the strength community generally fall in this range:
| Goal | Daily dose | Cadence | Duration |
|---|---|---|---|
| General recovery | 250 mcg | Once daily | 4–6 weeks |
| Acute injury | 500 mcg | Twice daily, near injury site | 6–8 weeks |
| Gut / GI focus | 250–500 mcg | Once daily, oral or SubQ | 4–8 weeks |
Doses are typically given subcutaneously, often near (but not into) the affected tissue. Most users cycle 4–8 weeks on, then take time off rather than running it indefinitely.
For specific protocols, see BPC-157 dosing protocols.
Reconstitution math
BPC-157 ships as a dry lyophilized powder. To inject it, you mix it with bacteriostatic water. The math:
5 mg vial + 2 mL BAC water = 2.5 mg/mL. A 250 mcg dose is then 0.1 mL — or 10 units on a U-100 insulin syringe.
Our reconstitution calculator handles the math live, including which insulin-syringe size to use.
Stacking BPC-157
The most-discussed stack is BPC-157 + TB-500. The pairing is rationalized as complementary mechanisms: BPC-157 drives angiogenesis and growth-factor upregulation locally, while TB-500 (a thymosin beta-4 fragment) promotes systemic cell migration and actin reorganization. People with stubborn tendon or ligament injuries report better results from the stack than either alone.
For the full breakdown, see BPC-157 vs TB-500 and stacking.
Side effects and safety profile
BPC-157 has a mild side-effect profile in the reported literature and self-experimentation logs. The most common reports are:
- Mild lethargy or sleepiness in the first few doses
- Headaches in some users (often resolves)
- Injection-site reactions (transient redness, itching)
- Nausea (rare, mostly with high oral doses)
The big open question is long-term safety in humans, particularly around angiogenesis and cancer risk. Because BPC-157 promotes blood-vessel formation, theoretical concern exists that it could feed an undetected tumor. The pre-clinical record does not show a tumor-promoting signal — but this hasn't been studied long-term in humans. Most users avoid running BPC-157 with any active or suspected malignancy.
Deeper coverage: BPC-157 side effects.
Legal and sourcing reality
In November 2023, the FDA declined to add BPC-157 to the 503A bulks list, meaning compounding pharmacies cannot legally compound it for prescription use in the United States. That pushed BPC-157 firmly back into the research-chemical market, which has its own quality-control and identity-purity issues. Anyone using BPC-157 today should be doing so with full awareness of the regulatory and supply-chain reality.
There is no FDA-approved version. There is no pharmaceutical brand. Every vial is from a research-chemical vendor, and quality varies dramatically.
Who should and shouldn't use BPC-157
This is education, not advice — talk to a clinician. But the patterns in user reports suggest BPC-157 is most useful for:
- Stubborn tendon, ligament, or soft-tissue injuries that haven't healed with rest and PT
- IBD, GERD, or other GI inflammation (where the oral route is most defensible)
- Athletes managing accumulating training damage
And least appropriate for:
- Anyone with a current or recent cancer diagnosis
- People with no specific recovery target (the side-effect profile is mild but not zero)
- Anyone unable or unwilling to verify vial identity and purity